{"id":937227,"date":"2026-02-17T09:38:08","date_gmt":"2026-02-17T14:38:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\/"},"modified":"2026-02-17T09:38:08","modified_gmt":"2026-02-17T14:38:08","slug":"dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\/","title":{"rendered":"Dyadic Applied BioSolutions and Proliant Health &amp; Biologicals Announce Commercial Launch of Recombinant Human Albumin"},"content":{"rendered":"<div class=\"mw_release\">\n<p>JUPITER, Fla. and ANKENY, Iowa, Feb.  17, 2026  (GLOBE NEWSWIRE) &#8212; Dyadic Applied BioSolutions (\u201cDyadic\u201d, \u201cwe\u201d, \u201cus\u201d, \u201cour\u201d, or the \u201cCompany\u201d) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Proliant Health &amp; Biologicals (\u201cProliant\u201d), a leading global producer of albumin and other purified proteins for life science, nutrition, and diagnostic applications, today announced the commercial launch of AlbuFree\u2122 DX, a recombinant human albumin (rHA) product produced using Dyadic\u2019s proprietary filamentous fungal expression technology.<\/p>\n<p>The launch of AlbuFree\u2122 DX underscores Dyadic\u2019s strategy to prioritize recombinant protein products that have clear commercial pathways and are supported by well-established end markets. Under the terms of the agreement, Dyadic will receive a share of profits from Proliant\u2019s commercial sales of recombinant human albumin products.<\/p>\n<p>\u201cThis launch is a clear validation of Dyadic\u2019s technology and our commercialization strategy,\u201d said Joe Hazelton, President and Chief Operating Officer of Dyadic. \u201cRecombinant human albumin is a well-understood product with broad adoption in cell culture and life science applications, making it an ideal fit for our platform and partner-driven commercialization model.\u201d<\/p>\n<p>Recombinant human albumin is a critical component in cell culture media and other life science applications, where demand is rising for animal-free, scalable, and supply-secure inputs. The launch of AlbuFree\u2122 DX marks the first major commercial step in Dyadic\u2019s growing portfolio of market-specific proteins and represents an important milestone in converting licensed programs into recurring revenue streams.<\/p>\n<p>\u201cProliant has decades of experience producing albumin at global scale and supplying customers through an established worldwide distribution network,\u201d said Chris Detzel, President and Chief Executive Officer of Proliant Health &amp; Biologicals. \u201cAlbuFree\u2122 DX builds on that foundation by adding a high-quality, animal-free recombinant human albumin to our diagnostic market portfolio, allowing us to meet growing customer demand while maintaining the consistency, reliability, and scale our customers expect. Further expansion of the AlbuFree\u2122 line is expected later this year with the next version specifically formulated for the cell culture market.\u201d<\/p>\n<p>\u201cThis milestone demonstrates that Dyadic\u2019s microbial platforms are well-suited for products that can be efficiently integrated into existing manufacturing, quality, and commercial infrastructures,\u201d Hazelton added. \u201cWe believe this further reinforces the applicability of Dyadic\u2019s technology for scalable commercialization in large, established markets.\u201d<\/p>\n<p>Dyadic continues to advance additional recombinant proteins for cell culture, life science, nutrition, and industrial applications through a combination of internal programs and strategic partnerships.<\/p>\n<p>\n        <strong>About Dyadic Applied BioSolutions<\/strong>\n      <\/p>\n<p>Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic\u2019s C1 and Dapibus\u2122 expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered programs. For more information about Dyadic, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3MkKEv0y00i96JYAjm1Z298PAAA_2VPHrR9Zpf5oQqwxWAGhi91yNdSBL0b5FlycGaLt4ogS0Wonr8iazg9WAQ==\" rel=\"nofollow\" target=\"_blank\"><strong><u>www.dyadic.com<\/u><\/strong><\/a><\/p>\n<p>\n        <strong>About Proliant Health &amp; Biologicals<\/strong>\n      <\/p>\n<p>Proliant Health &amp; Biologicals is a global leader in the production of purified bovine and recombinant proteins, serving life science, diagnostic, nutrition, and medical markets worldwide. With decades of manufacturing expertise, vertically integrated operations, and a global network of distributors and customers, Proliant is recognized for its scale, quality, and reliability in albumin and specialty protein supply. For more information about AlbuFree\u2122 DX and Proliant please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fW0N_uWKn_K2RHZqu0dnyBbzaE5SqhBJ6XVELU-lmBDc7JmusZKsP_4YCvlJ8reJT6vctZ0uxjHxDD1CcGA-Xw==\" rel=\"nofollow\" target=\"_blank\"><strong>phb1.com<\/strong><\/a><\/p>\n<p>\n        <strong>Safe Harbor Regarding Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, including those regarding Dyadic\u2019s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of Dyadic\u2019s clinical trial and interest in its protein production platforms, Dyadic\u2019s research projects and third-party collaborations, as well as the availability of necessary funding. Forward-looking statements involve many risks, uncertainties or other factors beyond Dyadic\u2019s control. These factors include, but are not limited to, the following: (i) Dyadic\u2019s history of net losses\u037e (ii) market and regulatory acceptance of Dyadic\u2019s microbial protein production platforms and other technologies\u037e (iii) failure to commercialize Dyadic\u2019s microbial protein production platforms or its other technologies; (iv) competition, including from alternative technologies\u037e (v) the results of nonclinical studies and clinical trials\u037e (vi) Dyadic\u2019s capital needs\u037e (vii) changes in global economic and financial conditions\u037e (viii) Dyadic\u2019s reliance on information technology\u037e (ix) Dyadic\u2019s dependence on third parties\u037e (x) government regulations and environmental, social and governance issues\u037e (xi) intellectual property risks; and (xii) Dyadic\u2019s ability to comply with the listing standards of the Nasdaq Stock Market LLC. For a more complete description of the risks that could cause Dyadic\u2019s actual results to differ from its current expectations, please see the section entitled \u201cRisk Factors\u201d in Dyadic\u2019s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic\u2019s periodic filings with the SEC, which are accessible on the SEC\u2019s website and at www.dyadic.com. All forward-looking statements speak only as of the date made, and except as required by applicable law, Dyadic assumes no obligation to publicly update any such forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in Dyadic\u2019s expectations.<\/p>\n<p>\n        <strong>Media contacts:<\/strong><\/p>\n<p>Dyadic Applied BioSolutions:<br \/>Ping Rawson<br \/>Chief Financial Officer<br \/>Phone: (561) 743-8333<br \/>Email:\u00a0<strong><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HukNBGjCEpIqEsh8LfqMdMGv5K1IjHebZQ-bgENzbhr0JK_7OddVOfojzG4sDdFgzAvEvC5ZO52myFGftko4Cw==\" rel=\"nofollow\" target=\"_blank\">ir@dyadic.com<\/a><\/u><\/strong><\/p>\n<p>Proliant Health and Biologicals:<br \/>Alexis Voss<br \/>Email:\u00a0 <strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8bOV5DRpYH98zQfCBjFNwxurLUNUVXUdAbzZllxElq-df_dVz4rI2fE2604Nci3NRCzupdYC2SVqVDRPZFosCKpIwcxhkiW8NgT9sqfP7dM=\" rel=\"nofollow\" target=\"_blank\">Alexis.voss@phb1.com<\/a><\/strong><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NTUzNSM3NDI3MjEwIzIwMTkyMTA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjdiZWQxZWMtOThhYi00ZWNlLTk3YzUtYWQ2ZjgwMzMxYzJhLTEwMzA3ODMtMjAyNi0wMi0xNy1lbg==\/tiny\/Dyadic-International-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>JUPITER, Fla. and ANKENY, Iowa, Feb. 17, 2026 (GLOBE NEWSWIRE) &#8212; Dyadic Applied BioSolutions (\u201cDyadic\u201d, \u201cwe\u201d, \u201cus\u201d, \u201cour\u201d, or the \u201cCompany\u201d) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Proliant Health &amp; Biologicals (\u201cProliant\u201d), a leading global producer of albumin and other purified proteins for life science, nutrition, and diagnostic applications, today announced the commercial launch of AlbuFree\u2122 DX, a recombinant human albumin (rHA) product produced using Dyadic\u2019s proprietary filamentous fungal expression technology. The launch of AlbuFree\u2122 DX underscores Dyadic\u2019s strategy to prioritize recombinant protein products that have clear commercial pathways and are supported by well-established end markets. Under the terms of the agreement, Dyadic will &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Dyadic Applied BioSolutions and Proliant Health &amp; Biologicals Announce Commercial Launch of Recombinant Human Albumin&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-937227","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Dyadic Applied BioSolutions and Proliant Health &amp; Biologicals Announce Commercial Launch of Recombinant Human Albumin - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dyadic Applied BioSolutions and Proliant Health &amp; Biologicals Announce Commercial Launch of Recombinant Human Albumin - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"JUPITER, Fla. and ANKENY, Iowa, Feb. 17, 2026 (GLOBE NEWSWIRE) &#8212; Dyadic Applied BioSolutions (\u201cDyadic\u201d, \u201cwe\u201d, \u201cus\u201d, \u201cour\u201d, or the \u201cCompany\u201d) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Proliant Health &amp; Biologicals (\u201cProliant\u201d), a leading global producer of albumin and other purified proteins for life science, nutrition, and diagnostic applications, today announced the commercial launch of AlbuFree\u2122 DX, a recombinant human albumin (rHA) product produced using Dyadic\u2019s proprietary filamentous fungal expression technology. The launch of AlbuFree\u2122 DX underscores Dyadic\u2019s strategy to prioritize recombinant protein products that have clear commercial pathways and are supported by well-established end markets. Under the terms of the agreement, Dyadic will &hellip; Continue reading &quot;Dyadic Applied BioSolutions and Proliant Health &amp; Biologicals Announce Commercial Launch of Recombinant Human Albumin&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-17T14:38:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NTUzNSM3NDI3MjEwIzIwMTkyMTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Dyadic Applied BioSolutions and Proliant Health &amp; Biologicals Announce Commercial Launch of Recombinant Human Albumin\",\"datePublished\":\"2026-02-17T14:38:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\\\/\"},\"wordCount\":944,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NTUzNSM3NDI3MjEwIzIwMTkyMTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\\\/\",\"name\":\"Dyadic Applied BioSolutions and Proliant Health &amp; Biologicals Announce Commercial Launch of Recombinant Human Albumin - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NTUzNSM3NDI3MjEwIzIwMTkyMTA=\",\"datePublished\":\"2026-02-17T14:38:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NTUzNSM3NDI3MjEwIzIwMTkyMTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NTUzNSM3NDI3MjEwIzIwMTkyMTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dyadic Applied BioSolutions and Proliant Health &amp; Biologicals Announce Commercial Launch of Recombinant Human Albumin\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dyadic Applied BioSolutions and Proliant Health &amp; Biologicals Announce Commercial Launch of Recombinant Human Albumin - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\/","og_locale":"en_US","og_type":"article","og_title":"Dyadic Applied BioSolutions and Proliant Health &amp; Biologicals Announce Commercial Launch of Recombinant Human Albumin - Market Newsdesk","og_description":"JUPITER, Fla. and ANKENY, Iowa, Feb. 17, 2026 (GLOBE NEWSWIRE) &#8212; Dyadic Applied BioSolutions (\u201cDyadic\u201d, \u201cwe\u201d, \u201cus\u201d, \u201cour\u201d, or the \u201cCompany\u201d) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Proliant Health &amp; Biologicals (\u201cProliant\u201d), a leading global producer of albumin and other purified proteins for life science, nutrition, and diagnostic applications, today announced the commercial launch of AlbuFree\u2122 DX, a recombinant human albumin (rHA) product produced using Dyadic\u2019s proprietary filamentous fungal expression technology. The launch of AlbuFree\u2122 DX underscores Dyadic\u2019s strategy to prioritize recombinant protein products that have clear commercial pathways and are supported by well-established end markets. Under the terms of the agreement, Dyadic will &hellip; Continue reading \"Dyadic Applied BioSolutions and Proliant Health &amp; Biologicals Announce Commercial Launch of Recombinant Human Albumin\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-17T14:38:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NTUzNSM3NDI3MjEwIzIwMTkyMTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Dyadic Applied BioSolutions and Proliant Health &amp; Biologicals Announce Commercial Launch of Recombinant Human Albumin","datePublished":"2026-02-17T14:38:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\/"},"wordCount":944,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NTUzNSM3NDI3MjEwIzIwMTkyMTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\/","name":"Dyadic Applied BioSolutions and Proliant Health &amp; Biologicals Announce Commercial Launch of Recombinant Human Albumin - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NTUzNSM3NDI3MjEwIzIwMTkyMTA=","datePublished":"2026-02-17T14:38:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NTUzNSM3NDI3MjEwIzIwMTkyMTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NTUzNSM3NDI3MjEwIzIwMTkyMTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyadic-applied-biosolutions-and-proliant-health-biologicals-announce-commercial-launch-of-recombinant-human-albumin\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Dyadic Applied BioSolutions and Proliant Health &amp; Biologicals Announce Commercial Launch of Recombinant Human Albumin"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/937227","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=937227"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/937227\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=937227"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=937227"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=937227"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}